User profiles for J. D. Gispert
 | Juan Domingo GispertNeuroimaging. BBRC-Fundació Pasqual Maragall. Centro Nacional de Investigaciones … Verified email at barcelonabeta.org Cited by 8696 |
[HTML][HTML] Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer’s
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
[HTML][HTML] Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…
disease are needed to facilitate the initial screening process of participants in disease-…
Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum
…, G Salvadó, M Shekari, G Operto, JD Gispert… - JAMA …, 2021 - jamanetwork.com
Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
TREM 2 is an innate immune receptor expressed on the surface of microglia. Loss‐of‐function
mutations of TREM 2 are associated with increased risk of Alzheimer's disease ( AD ). …
mutations of TREM 2 are associated with increased risk of Alzheimer's disease ( AD ). …
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
…, S Landolfi, Y Fernández, JR Herance, JD Gispert… - Nature medicine, 2012 - nature.com
The Wnt–β-catenin and PI3K-AKT-FOXO3a pathways have a central role in cancer. AKT
phosporylates FOXO3a, relocating it from the cell nucleus to the cytoplasm, an effect that is …
phosporylates FOXO3a, relocating it from the cell nucleus to the cytoplasm, an effect that is …
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ …
…, M Milà‐Alomà, JD Gispert… - EMBO molecular …, 2020 - embopress.org
In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
Global and regional gray matter reductions in ADHD: a voxel-based morphometric study
…, JC Soliva, M Rovira, J Tomas, C Raheb, JD Gispert… - Neuroscience …, 2005 - Elsevier
Attention deficit hyperactivity disorder (ADHD) is a developmental disorder characterized by
inattentiveness, motor hyperactivity and impulsivity. According to neuroimaging data, the …
inattentiveness, motor hyperactivity and impulsivity. According to neuroimaging data, the …
[HTML][HTML] Secondary prevention of Alzheimer's dementia: neuroimaging contributions
…, M Ewers, C Foley, JD Gispert… - Alzheimer's research & …, 2018 - Springer
Background In Alzheimer’s disease (AD), pathological changes may arise up to 20 years
before the onset of dementia. This pre-dementia window provides a unique opportunity for …
before the onset of dementia. This pre-dementia window provides a unique opportunity for …
The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem
…, B García‐Cuartero, JD Gispert… - Journal of …, 2005 - Wiley Online Library
In the present work, several experimental approaches were used to determine the presence
of the glucagon‐like peptide‐1 receptor (GLP‐1R) and the biological actions of its ligand in …
of the glucagon‐like peptide‐1 receptor (GLP‐1R) and the biological actions of its ligand in …
Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOECP-SEOR …
…, RM Manero, X Durán, JD Gispert… - Journal of Clinical …, 2021 - ingentaconnect.com
PURPOSE Radiation dose received by the neural stem cells of the hippocampus during
whole-brain radiotherapy has been associated with neurocognitive decline. The key concern …
whole-brain radiotherapy has been associated with neurocognitive decline. The key concern …